ChromaCure

ChromaCure's mission is to discover and develop first-class small molecule therapies to meet unmet needs in oncology. The company is developing an inhibitor of a novel target based on research conducted at the Blanpain Lab, the Stem Cell and Cancer Laboratory at the Université Libre de Bruxelles (ULB), which is a key regulator of tumor initiation and progression.